Cumulative HbA1c Exposure as a CVD Risk in Patients With Type 2 Diabetes: a Post Hoc Analysis of ACCORD Trial
Source : https://pubmed.ncbi.nlm.nih.gov/37952600/
Higher cumulative HbA1c exposure was significantly associated with an increased risk of the primary outcome, all-cause mortality and cardiovascular death among T2D patients.
Participants in the intensive-therapy group with high baseline HbA1c and cumulative HbA1c exposure had a significantly higher risk of primary outcome, all-cause mortality, and CV-related death.
Neuropeptide Y Is Elevated in Heart Failure and Is an Independent Predictor of Outcomes
Source : https://pubmed.ncbi.nlm.nih.gov/37937329/
Peripherally measured NPY is an independent predictor of all-cause and cardiovascular death even after adjustment for other prognostic variables, including BNP.
Peripherally measured NPY is an independent predictor of all cause and CV death even after adjustment for other prognostic variables, including BNP.
Use of MHT in Women With Cardiovascular Disease: a Systematic Review and Meta-Analysis
Source : https://pubmed.ncbi.nlm.nih.gov/37933495/
This systematic review assesses the effect of menopausal hormone therapy (MHT) on cardiovascular outcomes and risk factors in postmenopausal women with cardiovascular disease (CVD).
No significant differences were observed between MHT users and controls regarding primary outcomes of nonfatal MI, CV-related death, or stroke. No differences in frequency of angina, HF, and TIAs were observed.
Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578385/
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a modest but significant increase in serum magnesium levels.
SGLT2 inhibitors in patients with diabetes mellitus have been efficacious for glycemic control, renal protection, decreasing the risk of atherosclerotic cardiovascular disease events, and reducing cardiac mortality.
Impact of SGLT2 Inhibitors on Patient Outcomes: a Network Meta-Analysis
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-02035-8
A comprehensive network meta-analysis comparing the effects of individual sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with and without comorbidities including diabetes mellitus (DM), heart failure (HF), and chronic kidney...
A network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin.